Atay Oguzhan sold $2.5M of BLLN

Atay Oguzhan (Chairman and CEO) sold 24,999 shares of BillionToOne, Inc. (BLLN) at an average of $100.32 ($98.63–$101.49, $2.51M total) across 8 trades on 2026-09-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Atay Oguzhan
Published Sep 16, 2026, 10:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 10:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Bearish
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNBearishLow
01

Why it matters

The disclosed sale may prompt short‑term price weakness, but the pre‑arranged nature tempers speculation.

02

Market read

Insider sell adds a modest bearish signal for BLLN; relevance limited to traders monitoring micro‑cap insider activity.

03

What to watch

Potential upcoming financing round or strategic partnership that prompted the insider to free cash.

Relevance 5/10Novelty 4/10Timing: filed 2026‑09‑16

Background

SEC Form 4 filing discloses an insider transaction by the company's chairman and CEO.

Company-level read

Ticker impact

$BLLNBearishMedium confidence
Context

CEO Atay Oguzhan sold 24,999 shares for $2.5M via a 10b5‑1 plan, leaving zero holdings.

Expected impact

modest short‑term dip, likely <2% unless reinforced by broader sentiment.

Evidence & confidence

The sale is sizable for a micro‑cap and executed through a pre‑arranged plan, but no other catalyst is present.

Market effects

Minimal; biotech/AI micro‑cap sector may see slight caution.

U.S. small‑cap market may register a marginal sell‑side bias.

Limited to investors tracking insider activity.

Counterpoint

The sale could be purely liquidity‑driven under a 10b5‑1 plan, not a lack of confidence.

Key entities

  • BillionToOne, Inc.

    Issuer of ticker BLLN, a micro‑cap listed on Nasdaq.

  • Atay Oguzhan

    Chairman and CEO of BillionToOne, executing a 10b5‑1 sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.